CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
about
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines.Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.
P2860
CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
CDKN1A-mediated responsiveness ...... to Aurora kinase-A inhibitors.
@en
CDKN1A-mediated responsiveness ...... to Aurora kinase-A inhibitors.
@nl
type
label
CDKN1A-mediated responsiveness ...... to Aurora kinase-A inhibitors.
@en
CDKN1A-mediated responsiveness ...... to Aurora kinase-A inhibitors.
@nl
prefLabel
CDKN1A-mediated responsiveness ...... to Aurora kinase-A inhibitors.
@en
CDKN1A-mediated responsiveness ...... to Aurora kinase-A inhibitors.
@nl
P2093
P2860
P356
P1476
CDKN1A-mediated responsiveness ...... to Aurora kinase-A inhibitors
@en
P2093
Hui-Ju Lin
Jang-Yang Chang
Jiann-Shiuh Chen
Kung-Chao Chang
Liang-Yi Hung
Ming-Ying Tsai
Nai-Feng Chen
Shu-Ting Yang
Tsai-Yun Chen
Wen-Chang Chang
P2860
P304
P356
10.1002/IJC.28708
P577
2014-01-13T00:00:00Z